MedTrace Logo

Netarsudil Use After Descemtorhexis Without Endothelial Keratoplasty

NCT04752020 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2024-03-13

No results posted yet for this study

Summary

This will be a prospective assessment of whether adjuvant Netarsudil use in patients undergoing Descemetorhexis without endothelial keratoplasty improves time to corneal clearance and post-operative central endothelial cell counts. The anticipated enrollment is 25 patients.

Conditions

  • Fuchs' Endothelial Dystrophy

Interventions

DRUG

Netarsudil Ophthalmic

Use of netarsudil after Descemetorhexis without endothelial keratoplasty

Sponsors & Collaborators

  • Massachusetts Eye and Ear Infirmary

    lead OTHER

Principal Investigators

  • Emma Davies, MD · Massachusetts Eye and Ear Infirmary

  • Sila E Bal, MD, MPH · Massachusetts Eye and Ear Infirmary

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-28
Primary Completion
2023-06-28
Completion
2023-12-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04752020 on ClinicalTrials.gov